FY103B Identified to Exhibit Profound Antineoplastic Effects in the Digestive Tract
12/10/14 10:30 Filed in: innovations | drug discovery | pharmaceutical company | cancer | FY103B | superior | NSAID | ibuprofen | intestinal
Researchers at FyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, have identified novel antineoplastic benefits from FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category. Read More...
FyMed Announces Top-Line Results Demonstrating Superiority of FY103B over Celecoxib in the Treatment of Pain and Inflammation
22/04/14 11:10 Filed in: innovations | drug discovery | pharmaceutical company | FY103B | superior | NSAID | ibuprofen
FyMed, Inc. today announced top-line results from studies of FY103B, its new NSAID candidate, which demonstrated significant superiority over celecoxib in terms of efficacy and safety. Read More...